{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:00:17Z","timestamp":1792425617915,"version":"4.5.0"},"reference-count":49,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T00:00:00Z","timestamp":1669075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Context<\/jats:title><jats:p>Cabergoline (CAB) is an off-label medical therapy for acromegaly, overshadowed by first-generation somatostatin receptor ligands, eg, octreotide (OCT).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This was a head-to-head comparison between OCT and CAB in inhibiting growth hormone (GH) secretion in primary cultures of GH- and GH\/prolactin (PRL)-secreting tumors; we also investigated the role of somatostatin (SST) and dopamine type 2 (D2R) receptor expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated the antisecretory effect of OCT and CAB, together with receptor mRNA expression, in 23 tumor cultures obtained from acromegaly patients referred to the Erasmus Medical Center (Rotterdam, The Netherlands). GH concentrations in cell culture media were determined after 72-hour OCT and CAB treatment (10 nM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>OCT showed a slightly higher efficacy compared with CAB (GH decrease \u221239.5% vs \u221232.5%, P = 0.079). The effect of the 2 drugs was superimposable in GH\/PRL co-secreting tumors (\u221242.1% vs \u221244.8%), where SST1 and D2R had a higher expression compared with the pure GH-secreting tumors (P = 0.020 and P = 0.026). OCT was more effective than CAB in 8\/23 cultures, while CAB was more effective than OCT in 3\/23 (CAB+ group). In CAB+ tumors, SST1 expression was higher compared with the other groups (P = 0.034). At receiver operating characteristic (ROC) curve analysis, SST1 and D2R discriminated between GH and GH\/PRL co-secretion (AUC 0.856, P = 0.013; AUC 0.822, P = 0.024). SST1 was the best predictor of CAB response (\u226550% GH reduction, AUC 0.913, P = 0.006; 80% sensitivity, 94% specificity).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>OCT is 5% to 10% more effective than CAB in vitro. SST1 mRNA expression can represent a reliable marker of GH\/PRL co-secreting tumors showing a preferential response to CAB treatment.<\/jats:p><\/jats:sec>","DOI":"10.1210\/clinem\/dgac675","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T17:55:57Z","timestamp":1669139757000},"page":"e98-e109","source":"Crossref","is-referenced-by-count":7,"title":["Dissecting the In Vitro Efficacy of Octreotide and Cabergoline in GH- and GH\/PRL-Secreting Pituitary Tumors"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-9208","authenticated-orcid":false,"given":"Federico","family":"Gatto","sequence":"first","affiliation":[{"name":"Endocrinology Unit, IRCCS Ospedale Policlinico San Martino , 16132 Genova , Italy"},{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"},{"name":"Pituitary Center Rotterdam, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2319-391X","authenticated-orcid":false,"given":"Richard A","family":"Feelders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"},{"name":"Pituitary Center Rotterdam, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M","family":"van Koetsveld","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadime","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian J C M M","family":"Neggers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"},{"name":"Pituitary Center Rotterdam, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aart-Jan","family":"van der Lelij","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"},{"name":"Pituitary Center Rotterdam, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Amar\u00f9","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Internal Medicine and Medical Specialties, University of Genoa , 16132 Genoa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1410-6143","authenticated-orcid":false,"given":"Diego","family":"Ferone","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, IRCCS Ospedale Policlinico San Martino , 16132 Genova , Italy"},{"name":"Endocrinology Unit, Department of Internal Medicine and Medical Specialties, University of Genoa , 16132 Genoa , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo J","family":"Hofland","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"},{"name":"Pituitary Center Rotterdam, Erasmus MC , 3015 GD, Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,11,22]]},"reference":[{"issue":"24","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12022-022-09703-7","article-title":"Overview of the 2022 WHO classification of pituitary tumors","volume":"33","author":"Asa","year":"2022","journal-title":"Endocr Pathol"},{"issue":"9","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A consensus statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nat Rev Endocrinol"},{"issue":"16","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.3390\/ijms20163940","article-title":"Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms","volume":"20","author":"Gatto","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1530\/EJE-19-0074","article-title":"ANNIVERSARY REVIEW: octreotide, 40 years later","volume":"181","author":"Lamberts","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11102-016-0782-6","article-title":"Cabergoline in acromegaly","volume":"20","author":"Kuhn","year":"2017","journal-title":"Pituitary"},{"issue":"4","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2023041309385917500_","first-page":"841","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of cabergoline, a prolactin-lowering drug, after administration of increasing oral doses (0.5, 1.0, and 1.5 milligrams) in healthy male volunteers","volume":"80","author":"Andreotti","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-014-0183-4","article-title":"Cabergoline treatment in acromegaly: cons","volume":"46","author":"Kasuki","year":"2014","journal-title":"Endocrine"},{"issue":"2","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s12020-014-0206-1","article-title":"Cabergoline treatment in acromegaly: pros","volume":"46","author":"Marazuela","year":"2014","journal-title":"Endocrine"},{"issue":"6","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/cen.13595","article-title":"Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands","volume":"88","author":"Kasuki","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","article-title":"Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage","volume":"91","author":"Cozzi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1385\/ENDO:20:3:299","article-title":"Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly","volume":"20","author":"Burt","year":"2003","journal-title":"Endocrine"},{"issue":"4","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1210\/jc.2007-1358","article-title":"Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy","volume":"93","author":"Ferone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1210\/jcem-60-6-1148","article-title":"Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH\/prolactin-containing pituitary adenomas","volume":"60","author":"Lamberts","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11102-020-01113-4","article-title":"Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells","volume":"24","author":"Cuny","year":"2021","journal-title":"Pituitary"},{"issue":"3-4","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1159\/000095536","article-title":"Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas","volume":"83","author":"Saveanu","year":"2006","journal-title":"Neuroendocrinology"},{"issue":"6","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2265.1989.tb00264.x","article-title":"Glycoprotein hormone alpha-subunit and prolactin release by cultured pituitary adenoma cells from acromegalic patients: correlation with GH release","volume":"30","author":"Hofland","year":"1989","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11102-016-0778-2","article-title":"Somatostatin and dopamine receptor regulation of pituitary somatotroph adenomas","volume":"20","author":"Ben-Shlomo","year":"2017","journal-title":"Pituitary"},{"issue":"6","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1210\/jc.2008-1826","article-title":"Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly","volume":"94","author":"Neto","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2023041309385917500_","first-page":"781","article-title":"Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes","volume":"85","author":"Jaquet","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1210\/jc.2003-031344","article-title":"The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro","volume":"89","author":"Hofland","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/jcem.86.1.7154","article-title":"The relationship between 24-hour growth hormone secretion and insulin-like growth factor I in patients with successfully treated acromegaly: impact of surgery or radiotherapy","volume":"86","author":"Peacey","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/BF03351007","article-title":"Isolation of large numbers of dispersed human pituitary adenoma cells obtained by aspiration","volume":"7","author":"Oosterom","year":"1984","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1210\/en.2013-1672","article-title":"\u03b2-Arrestin 1 and 2 and G protein-coupled receptor kinase 2 expression in pituitary adenomas: role in the regulation of response to somatostatin analogue treatment in patients with acromegaly","volume":"154","author":"Gatto","year":"2013","journal-title":"Endocrinology"},{"key":"2023041309385917500_","author":"Gatto"},{"issue":"12","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"E1880","DOI":"10.1210\/jc.2013-1987","article-title":"Preoperative normalization of cortisol levels in Cushing's Disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists","volume":"98","author":"van der Pas","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1210\/jc.2003-030837","article-title":"Dopamine receptor expression and function in corticotroph pituitary tumors","volume":"89","author":"Pivonello","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1210\/jc.2008-2101","article-title":"Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas","volume":"94","author":"de Bruin","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-16-0332","article-title":"Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro","volume":"231","author":"Ibanez-Costa","year":"2016","journal-title":"J Endocrinol"},{"issue":"1","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"1","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2265.1987.tb00834.x","article-title":"A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients","volume":"27","author":"Lamberts","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/EJE-08-0822","article-title":"Pituitary-independent effect of octreotide on IGF1 generation","volume":"160","author":"Pokrajac","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-10-0969","article-title":"Hypothesis: extra-hepatic acromegaly: a new paradigm?","volume":"164","author":"Neggers","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/jcp.2005.026914","article-title":"Mapping of somatostatin receptor types in GH or\/and PRL producing pituitary adenomas","volume":"59","author":"Thodou","year":"2006","journal-title":"J Clin Pathol"},{"issue":"9","key":"2023041309385917500_","first-page":"3268","article-title":"Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas","volume":"84","author":"Jaquet","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1530\/EJE-07-0806","article-title":"Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas","volume":"158","author":"Fusco","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1210\/jc.2002-021825","article-title":"Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion","volume":"88","author":"Zatelli","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1749-6632.2010.05511.x","article-title":"Somatostatin and its receptors from fish to mammals","volume":"1200","author":"Gahete","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1210\/mend.14.2.0419","article-title":"Dual regulation of somatostatin receptor subtype 1 gene expression by Pit-1 in anterior pituitary GH3 cells","volume":"14","author":"Baumeister","year":"2000","journal-title":"Mol Endocrinol"},{"issue":"15","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/pros.23426","article-title":"Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer","volume":"77","author":"Pedraza-Arevalo","year":"2017","journal-title":"Prostate"},{"issue":"1","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1038\/s41598-022-12955-2","article-title":"Data mining analyses for precision medicine in acromegaly: a proof of concept","volume":"12","author":"Gil","year":"2022","journal-title":"Sci Rep"},{"issue":"4","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrg3185","article-title":"Insights into the regulation of protein abundance from proteomic and transcriptomic analyses","volume":"13","author":"Vogel","year":"2012","journal-title":"Nat Rev Genet"},{"issue":"17","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"14027","DOI":"10.1074\/jbc.M006084200","article-title":"Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A)","volume":"276","author":"Pfeiffer","year":"2001","journal-title":"J Biol Chem"},{"issue":"4","key":"2023041309385917500_","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s11102-009-0175-1","article-title":"Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment","volume":"12","author":"Casarini","year":"2009","journal-title":"Pituitary"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgac675\/47658243\/dgac675.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/5\/e98\/49873789\/dgac675.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/5\/e98\/49873789\/dgac675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T15:17:52Z","timestamp":1701443872000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/5\/e98\/6840299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,22]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,11,22]]},"published-print":{"date-parts":[[2023,4,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgac675","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,5,1]]},"published":{"date-parts":[[2022,11,22]]}}}